NI202100085A - Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento - Google Patents
Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamentoInfo
- Publication number
- NI202100085A NI202100085A NI202100085A NI202100085A NI202100085A NI 202100085 A NI202100085 A NI 202100085A NI 202100085 A NI202100085 A NI 202100085A NI 202100085 A NI202100085 A NI 202100085A NI 202100085 A NI202100085 A NI 202100085A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pharmaceutical composition
- variant
- human
- present disclosure
- amino acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 3
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 title 1
- 101710185730 Hyaluronidase A Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000010254 subcutaneous injection Methods 0.000 title 1
- 239000007929 subcutaneous injection Substances 0.000 title 1
- 101100178973 Homo sapiens SPAM1 gene Proteins 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 abstract 1
- 101150055528 SPAM1 gene Proteins 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a una composición farmacéutica que incluye (a) un medicamento y (B) una variante de PH20 humana. La variante de la PH20 humana incluida en la composición farmacéutica según la presente divulgación incluye sustitución(es) de residuos de aminoácidos en una o más regiones seleccionadas de una región de hélice alfa 8 (S347 a C381) y una región de enlace (A333 a R346) entre la hélice alfa 7 y la hélice alfa 8 en la PH20 humana de tipo salvaje que tiene la secuencia de aminoácidos de SEC ID NO: 1, en la que el (los) residuo(s) de aminoácidos situado(s) en la N-terminal o C-terminal se escinde(n) selectivamente. Además, la composición farmacéutica según la presente divulgación puede incluir además un aditivo farmacéuticamente aceptable, en particular un estabilizador. La composición farmacéutica según la presente divulgación puede máximizar el efecto terapéutico de un medicamento utilizado en combinación con la misma, debido al efecto de las variantes humanas de PH20.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190033880 | 2019-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202100085A true NI202100085A (es) | 2021-12-06 |
Family
ID=72611090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202100085A NI202100085A (es) | 2019-03-25 | 2021-09-22 | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20210363270A1 (es) |
| EP (1) | EP3785701A4 (es) |
| JP (3) | JP7295150B2 (es) |
| KR (3) | KR20230037691A (es) |
| CN (3) | CN116870164A (es) |
| AU (2) | AU2020248612B9 (es) |
| BR (1) | BR112021019076A2 (es) |
| CA (1) | CA3131052A1 (es) |
| CL (1) | CL2021002464A1 (es) |
| CO (1) | CO2021012380A2 (es) |
| CR (1) | CR20210489A (es) |
| DO (1) | DOP2021000197A (es) |
| EA (1) | EA202192588A1 (es) |
| EC (1) | ECSP21070640A (es) |
| IL (1) | IL286539A (es) |
| JO (1) | JOP20210262A1 (es) |
| MX (1) | MX2021011278A (es) |
| NI (1) | NI202100085A (es) |
| PE (1) | PE20220283A1 (es) |
| SG (1) | SG11202110512WA (es) |
| WO (1) | WO2020197230A1 (es) |
| ZA (2) | ZA202108027B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2749620T3 (es) | 2011-12-30 | 2020-03-23 | Halozyme Inc | Variantes de polipéptidos de PH20, formulaciones y usos de los mismos |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| WO2019217927A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
| AU2019311658B2 (en) * | 2018-07-25 | 2022-10-20 | Alteogen, Inc | Novel hyaluronidase variants and pharmaceutical composition comprising the same |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| US20230250408A1 (en) * | 2020-01-23 | 2023-08-10 | Alteogen Inc. | Novel hyaluronidase variants with improved stability and pharmaceutical composition comprising the same |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
| EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| PE20240820A1 (es) | 2020-12-28 | 2024-04-18 | Bristol Myers Squibb Co | Composiciones de anticuerpos y metodos de uso de los mismos |
| IL310608A (en) | 2021-08-02 | 2024-04-01 | argenx BV | Dosage forms for subcutaneous administration |
| KR20240055077A (ko) | 2021-09-14 | 2024-04-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 히알루로니데이스를 이용한 농축된 항체 제형의 촉진된 전달 |
| WO2023075506A1 (ko) * | 2021-10-29 | 2023-05-04 | (주)알테오젠 | 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물 |
| WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| WO2023169986A1 (en) * | 2022-03-07 | 2023-09-14 | Mabxience Research, S.L. | Stable formulations for antibodies |
| KR20230150203A (ko) * | 2022-04-20 | 2023-10-30 | 주식회사 알토스바이오로직스 | 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도 |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2023249408A1 (ko) * | 2022-06-22 | 2023-12-28 | (주)알테오젠 | N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도 |
| WO2024005502A1 (ko) * | 2022-06-29 | 2024-01-04 | 주식회사 오디스젠 | 중성 ph에서 활성을 나타내는 히알루로니다제 hyal1 변이체 |
| KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
| KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004024041D1 (de) * | 2003-03-05 | 2009-12-24 | Halozyme Inc | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen |
| EP1945662A2 (en) * | 2005-11-10 | 2008-07-23 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
| TWI532498B (zh) * | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| NZ601248A (en) * | 2008-04-14 | 2014-06-27 | Halozyme Inc | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| CA2746181C (en) * | 2008-12-09 | 2016-03-15 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| ES2749620T3 (es) * | 2011-12-30 | 2020-03-23 | Halozyme Inc | Variantes de polipéptidos de PH20, formulaciones y usos de los mismos |
| TW201534726A (zh) * | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| US20170218382A1 (en) * | 2014-07-31 | 2017-08-03 | National University Corporation Kobe University | Secretion Signal Peptide, And Protein Secretory Production And Cell Surface Display Using Said Secretion Signal Peptide |
| ES2727137T3 (es) * | 2014-08-28 | 2019-10-14 | Halozyme Inc | Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario |
| KR20190090394A (ko) * | 2016-11-30 | 2019-08-01 | 메모리얼 슬로안 케터링 캔서 센터 | 억제제-작용화된 초소형 나노입자 및 이의 방법 |
| CN116531511A (zh) * | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| AU2019311658B2 (en) * | 2018-07-25 | 2022-10-20 | Alteogen, Inc | Novel hyaluronidase variants and pharmaceutical composition comprising the same |
-
2020
- 2020-03-24 SG SG11202110512WA patent/SG11202110512WA/en unknown
- 2020-03-24 US US17/052,952 patent/US20210363270A1/en active Pending
- 2020-03-24 CN CN202310416462.0A patent/CN116870164A/zh active Pending
- 2020-03-24 CR CR20210489A patent/CR20210489A/es unknown
- 2020-03-24 CA CA3131052A patent/CA3131052A1/en active Pending
- 2020-03-24 EA EA202192588A patent/EA202192588A1/ru unknown
- 2020-03-24 WO PCT/KR2020/003975 patent/WO2020197230A1/ko active Application Filing
- 2020-03-24 MX MX2021011278A patent/MX2021011278A/es unknown
- 2020-03-24 JP JP2020569741A patent/JP7295150B2/ja active Active
- 2020-03-24 PE PE2021001563A patent/PE20220283A1/es unknown
- 2020-03-24 KR KR1020237007559A patent/KR20230037691A/ko active Search and Examination
- 2020-03-24 EP EP20776465.5A patent/EP3785701A4/en active Pending
- 2020-03-24 JO JOP/2021/0262A patent/JOP20210262A1/ar unknown
- 2020-03-24 CN CN202310758097.1A patent/CN117100867A/zh active Pending
- 2020-03-24 CN CN202080003052.8A patent/CN112203642A/zh active Pending
- 2020-03-24 KR KR1020207030248A patent/KR102650991B1/ko active IP Right Grant
- 2020-03-24 AU AU2020248612A patent/AU2020248612B9/en active Active
- 2020-03-24 BR BR112021019076A patent/BR112021019076A2/pt unknown
- 2020-03-24 KR KR1020227016935A patent/KR102507853B1/ko active IP Right Grant
-
2021
- 2021-09-19 IL IL286539A patent/IL286539A/en unknown
- 2021-09-22 CL CL2021002464A patent/CL2021002464A1/es unknown
- 2021-09-22 EC ECSENADI202170640A patent/ECSP21070640A/es unknown
- 2021-09-22 CO CONC2021/0012380A patent/CO2021012380A2/es unknown
- 2021-09-22 DO DO2021000197A patent/DOP2021000197A/es unknown
- 2021-09-22 NI NI202100085A patent/NI202100085A/es unknown
- 2021-10-20 ZA ZA2021/08027A patent/ZA202108027B/en unknown
-
2022
- 2022-04-18 JP JP2022068166A patent/JP7166478B2/ja active Active
- 2022-05-13 US US17/744,575 patent/US20220289864A1/en active Pending
- 2022-08-22 ZA ZA2022/09369A patent/ZA202209369B/en unknown
-
2023
- 2023-02-24 JP JP2023026863A patent/JP2023078146A/ja active Pending
-
2024
- 2024-02-23 AU AU2024201238A patent/AU2024201238A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202100085A (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| MX2020009824A (es) | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| AR091866A1 (es) | Analogos del glucagon | |
| AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
| NO345236B1 (no) | Glukagonlignende peptid-2 (GLP-2) analoger, farmasøytiske sammensetninger inneholdende slike og anvendelse for fremstillingen av et medikament for behandlingen og/eller forebyggingen av en mage- og tarmrelatert lidelse, samt nukleinsyremolekyl, ekspresjonsvektor, vertscelle og fremgangsmåter for fremstilling av GLP-2 analogene og et terapeutisk sett. | |
| PE20191203A1 (es) | Variantes de alfa-glucosidasa acida y usos de las mismas | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| MX2022008060A (es) | Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. | |
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| AR096162A1 (es) | Péptidos terapéuticos | |
| JP2014526254A5 (es) | ||
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| AR114389A1 (es) | Composición farmacéutica que comprende péptido tipo apl | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| CL2020002718A1 (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos. | |
| US20180170983A1 (en) | New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment | |
| PE20220500A1 (es) | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 | |
| AR061825A1 (es) | Analogos del peptido intestinal vasoactivo (vip) | |
| PE20210185A1 (es) | Apirasas solubilizadas, metodos y usos | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| AR119231A1 (es) | Agonistas de il2 | |
| PE20211772A1 (es) | Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados |